You are here

Articles

Trying to Calculate the Economic Value of Dasatinib or Nilotinib for Imatinib-Resistant CML

published: 31 March 2013

Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors

published: 27 March 2013

Nilotinib is associated with a reduced incidence of BCR-ABL mutations versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

published: 27 March 2013

EMA approves marketing authorisation for ponatinib/Iclusig

published: 23 March 2013

Is going for cure in chronic myeloid leukemia possible and justifiable? Francois-Xavier Mahon 1,2

published: 15 March 2013

Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure? Junia V. Melo1 and David M. Ross2

published: 15 March 2013

CML Stem Cell Burden at Diagnosis Associated With Treatment Outcomes

published: 14 March 2013

Oncology Enters Era of Genomics: Sledge Calls for Overhaul of Clinical Trials System

published: 13 March 2013

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

published: 10 March 2013

Suboptimal Responses in Chronic Myeloid Leukemia

published: 10 March 2013

Monitoring after successful therapy for chronic myeloid leukemia. Susan Branford

published: 6 March 2013

Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays? David T. Yeung 1-3 and Susan Branford 1,3

published: 6 March 2013

Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia. David Marin

published: 6 March 2013

When .0055% Matters- The Ozunaverse

published: 2 March 2013

“Borne Out of Necessity and Data”: Conquering Mutations in Leukemia By Jessica Wapner Posted: February 6, 2013

published: 28 February 2013

Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients

published: 27 February 2013

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

published: 22 February 2013

BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

published: 6 February 2013

Enzyme Accelerates Malignant Stem Cell Cloning in Chronic Myeloid Leukemia

published: 4 February 2013

FDA approves Gleevec for children with acute lymphoblastic leukemia

published: 26 January 2013